Update on the Pharmacologic Agents for Dyslipidemia / 임상당뇨병
Journal of Korean Diabetes
;
: 269-275, 2015.
Article
Dans Coréen
| WPRIM
| ID: wpr-726852
ABSTRACT
Although statins have demonstrated consistent and strong effects on cardiovascular prevention, non-statin drugs have failed to show additional clinical benefit. Consequently, statins are currently recommended as first-line therapy in dyslipidemia. On the contrary, non-statin drugs are indicated in limited cases in which statins are not sufficiently effective or intolerable. A recent trial on ezetimibe provides evidence supporting further prescription of this agent. Proprotein convertase subtilisin-kexin type 9 inhibitors have strong low-density lipoprotein-cholesterol-lowering effects and were just approved in Western countries. However, results of clinical outcomes are not yet available. Other non-statin lipid-modifying agents have their own roles and limitations. Thus, it is important to have correct knowledge on these agents for optimal treatment of dyslipidemic patients.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Acides gras omega-3
/
Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase
/
Proprotein convertases
/
Dyslipidémies
/
Protéines de transfert des esters de cholestérol
/
Ordonnances
/
Acides fibriques
/
Ézétimibe
/
Acide nicotinique
Limites du sujet:
Humains
langue:
Coréen
Texte intégral:
Journal of Korean Diabetes
Année:
2015
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS